C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan

What You Should Know:

– C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research. 

– Under this agreement, RG will work with C2i Genomics to commercialize its C2intelligence cloud-based platform and the C2inform MRD test for pharmaceutical and clinical research and eventually for commercial clinical testing in Japan. C2i’s technology allows cancer tumor burden monitoring using ultra-sensitive whole genome sequencing (WGS) for personalized medicine and accelerated drug development. This collaboration will build on RG’s current capabilities to provide MRD detection for hematology by expanding its MRD capabilities across all solid tumors.

– Now in Japan through the company’s agreement with RG, this collaboration follows several C2i Genomics global partnerships, most recently with AstraZeneca in the US, Karkinos Healthcare in India, OncoDNA across the EU, and SouthEast Asia with NovogeneAIT Genomics.

genomics
healthcare
ai
personalized medicine
medicine
pharmaceutical